

## Complete Summary

---

### GUIDELINE TITLE

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies.

### BIBLIOGRAPHIC SOURCE(S)

Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. Diabetes Care 2004 Aug; 27(8): 2067-73. [105 references] [PubMed](#)

### GUIDELINE STATUS

This is the current release of the guideline.

## COMPLETE SUMMARY CONTENT

SCOPE  
 METHODOLOGY - including Rating Scheme and Cost Analysis  
 RECOMMENDATIONS  
 EVIDENCE SUPPORTING THE RECOMMENDATIONS  
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
 QUALIFYING STATEMENTS  
 IMPLEMENTATION OF THE GUIDELINE  
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
 CATEGORIES  
 IDENTIFYING INFORMATION AND AVAILABILITY  
 DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

- Type 2 diabetes mellitus
- Overweight (body mass index [BMI] 25.0-29.9 kilograms per meter squared [kg/m<sup>2</sup>])
- Obesity (BMI  $\geq$ 30.0 kg/m<sup>2</sup>)

### GUIDELINE CATEGORY

Management  
 Prevention

### CLINICAL SPECIALTY

Endocrinology  
Family Practice  
Internal Medicine  
Nutrition  
Preventive Medicine

#### INTENDED USERS

Advanced Practice Nurses  
Dietitians  
Nurses  
Physician Assistants  
Physicians

#### GUIDELINE OBJECTIVE(S)

To review the important role of weight management in the prevention and management of type 2 diabetes and to describe strategies for achieving and maintaining a healthy body weight through lifestyle modification

#### TARGET POPULATION

Overweight and obese individuals at risk of or with type 2 diabetes

#### INTERVENTIONS AND PRACTICES CONSIDERED

Weight management through lifestyle modification including:

- Diet
- Physical activity

#### MAJOR OUTCOMES CONSIDERED

- Weight loss
- Glycemic control (fasting blood glucose concentrations)
- Use of diabetes medications
- Risk factors for cardiovascular disease (blood pressure, lipid concentrations, serum markers of inflammation)
- Development of type 2 diabetes in high-risk groups

### METHODOLOGY

#### METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

#### DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

#### NUMBER OF SOURCE DOCUMENTS

Not stated

#### METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

#### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

#### METHODS USED TO ANALYZE THE EVIDENCE

Review  
Review of Published Meta-Analyses

#### DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

#### METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

#### DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

#### RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

#### COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

#### METHOD OF GUIDELINE VALIDATION

External Peer Review  
Internal Peer Review

#### DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

American Diabetes Association Statements are reviewed externally and also by the Professional Practice Committee for overall content.

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

Overweight and obesity are strongly linked to the development of type 2 diabetes and can complicate its management. Obesity is also an independent risk factor for hypertension and dyslipidemia as well as cardiovascular disease, which is the major cause of death in those with diabetes. Moderate weight loss improves glycemic control, reduces cardiovascular disease risk, and can prevent the development of type 2 diabetes in those with pre-diabetes. Therefore, weight loss is an important therapeutic strategy in all overweight or obese persons who have type 2 diabetes or are at risk for developing diabetes.

#### Specific Recommendations

- Weight loss is recommended for all overweight (body mass index [BMI] 25.0-29.9 kilograms per meter squared [ $\text{kg/m}^2$ ]) or obese (BMI  $\geq 30.0 \text{ kg/m}^2$ ) adults who have, or who are at risk for developing, type 2 diabetes.
- The primary approach for achieving weight loss is therapeutic lifestyle change, which includes a reduction in energy intake and an increase in physical activity.
- A moderate decrease in caloric intake (500-1,000 kilocalories per day [ $\text{kcal/day}$ ]) will result in a slow but progressive weight loss (1-2 pounds per week). For most patients, weight loss diets should supply at least 1,000-1,200  $\text{kcal/day}$  for women and 1,200-1,600  $\text{kcal/day}$  for men.
- Overweight or obese patients with diabetes are encouraged to adopt the dietary recommendations known to reduce the risk of coronary heart disease (outlined in Tables 3 and 4 of the original guideline document). In conjunction with a moderate reduction in caloric intake (500-1,000  $\text{kcal/day}$ ), this diet is likely to result in moderate weight loss as well as improvement in cardiovascular risk factors. Dietary guidance should be tailored to each person, allowing for individual food preferences and approaches to reducing caloric intake.
- Physical activity is an important component of a comprehensive weight management program. Regular, moderate-intensity physical activity enhances long-term weight maintenance. Regular activity also improves insulin sensitivity, glycemic control, and selected risk factors for cardiovascular disease (i.e., hypertension and dyslipidemia), and increased aerobic fitness decreases the risk of coronary heart disease.
- Initial physical activity recommendations should be modest, based on the patient's willingness and ability, gradually increasing the duration and frequency to 30 to 45 minutes of moderate aerobic activity, 3 to 5 days per week, when possible. Greater activity levels of at least 1 hour per day of moderate (walking) or 30 minutes per day of vigorous (jogging) activity may be needed to achieve successful long-term weight loss.

### CLINICAL ALGORITHM(S)

None provided

## EVIDENCE SUPPORTING THE RECOMMENDATIONS

### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

## BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

### POTENTIAL BENEFITS

#### Benefits of Weight Loss

- Moderate weight loss (5% of body weight) can improve insulin action, decrease fasting blood glucose concentrations, and reduce the need for diabetes medications.
- Weight loss has important additional health benefits in patients with diabetes because it improves other risk factors for cardiovascular disease by decreasing blood pressure, improving serum lipid concentrations (decrease in serum triglycerides, total cholesterol, and low-density lipoprotein [LDL] cholesterol and increase in serum high-density lipoprotein [HDL] cholesterol concentrations), and reducing serum markers of inflammation.

#### Benefits of Physical Activity

Regular exercise and aerobic fitness improve insulin sensitivity and glycemic control, may decrease the risk of developing diabetes, and may reduce overall mortality in patients who have type 2 diabetes.

### POTENTIAL HARMS

Not stated

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

Although many different dietary approaches may result in short-term weight loss, the limitation of most diets is poor long-term compliance and weight regain. The optimal dietary macronutrient composition that facilitates lasting and safe weight loss is not known.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Living with Illness  
Staying Healthy

### IOM DOMAIN

Effectiveness  
Patient-centeredness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. Diabetes Care 2004 Aug; 27(8):2067-73. [105 references] [PubMed](#)

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2004 Aug

### GUIDELINE DEVELOPER(S)

American Diabetes Association - Professional Association  
American Society for Clinical Nutrition - Professional Association  
North American Association for the Study of Obesity - Professional Association

### SOURCE(S) OF FUNDING

American Diabetes Association (ADA)

### GUIDELINE COMMITTEE

Not stated

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Authors: Samuel Klein, MD, Division of Geriatrics and Nutritional Sciences and Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri; Nancy F. Sheard, SCD, RD, Department of Family Practice,

University of Vermont, Burlington, Vermont; Xavier Pi-Sunyer, MD, MPH, Division of Endocrinology, Diabetes and Nutrition, St. Luke's—Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York New York; Anne Daly, MS, RD, BC-ADM, CDE, Springfield Diabetes & Endocrine Center, Springfield, Illinois; Judith Wylie-Rosett, EDD, RD, Division of Health, Behavior and Nutrition, Albert Einstein College of Medicine, Bronx, New York; Karmeen Kulkarni, MS, RD, BC-ADM, CDE, St Mark's Diabetes Center, Salt Lake City, Utah; Nathaniel G. Clark, MD, MS, RD, American Diabetes Association, Alexandria, Virginia

#### FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Samuel Klein, MD is a member of the Obesity and Diabetes Educational Council, which is funded by an unrestricted educational grant provided by Roche Laboratories, is on the Enteromedics Medical Advisory Board, has received honoraria from Merck, and has received research support from Transneuronix.

Judith Wylie-Rosett, EDD, RD has received research funding from the Dr. Robert C. Atkins Foundation.

#### GUIDELINE STATUS

This is the current release of the guideline.

#### GUIDELINE AVAILABILITY

Electronic copies: Available from the [American Diabetes Association \(ADA\) Web site](#).

Print copies: Available from the American Diabetes Association, 1701 North Beauregard Street, Alexandria, VA 22311.

#### AVAILABILITY OF COMPANION DOCUMENTS

None available

#### PATIENT RESOURCES

None available

#### NGC STATUS

This NGC summary was completed by ECRI on April 18, 2005.

#### COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is copyrighted by the American Diabetes Association (ADA).

For information on guideline reproduction, please contact Alison Favors, Manager, Rights and Permissions by e-mail at [permissions@diabetes.org](mailto:permissions@diabetes.org).

For information about the use of the guidelines, please contact the Clinical Affairs Department at (703) 549-1500 ext. 1692.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006



